Obalon Therape…
ProfileJobs (2)

Obalon Therapeutics

Suggest Edit
    • Healthcarehealthtechmedical devicestherapy
    Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize treatment of chronic disease. As a company, we believe in the fundamental value of imagination and invention, combined with rigorous testing and analysis, to ensure the highest levels of safety and performance. The result is a user-focused approach that deploys the power of advanced technological thinking to support clinical treatment objectives.
    Revenue(FY, 2017)
    $9.9 M
    Market capitalization(2019-01-16)
    $39.6 M

    Employee Rating

    3.0More
    TypePublic
    HQCarlsbad, US
    Founded2008
    Size (employees)91 (est)
    Websiteobalon.com
    Obalon Therapeutics was founded in 2008 and is headquartered in Carlsbad, US
    Report incorrect company information

    Viewing summary data as a guest

    Sign up for free to see all data

    Key People/Management at Obalon Therapeutics

    Mark Brister

    Mark Brister

    VP of R&D
    Nooshin Hussainy

    Nooshin Hussainy

    Financial Controller
    Show more

    Obalon Therapeutics Office Locations

    Obalon Therapeutics has an office in Carlsbad
    Carlsbad, US (HQ)
    f 5421 Avenida Encinas
    Show all (1)
    Report incorrect company information

    Obalon Therapeutics Financials and Metrics

    Obalon Therapeutics Revenue

    Obalon Therapeutics's revenue was reported to be $9.91 m in FY, 2017
    USD

    Revenue (Q3, 2018)

    		3.0m

    Gross profit (Q3, 2018)

    		1.6m

    Gross profit margin (Q3, 2018), %

    		52.5%

    Net income (Q3, 2018)

    		(6.7m)

    EBIT (Q3, 2018)

    		(6.6m)

    Market capitalization (16-Jan-2019)

    		39.6m

    Closing stock price (16-Jan-2019)

    		1.7

    Cash (30-Sep-2018)

    		21.6m
    Obalon Therapeutics's current market capitalization is $39.6 m.
    Annual
    USDFY, 2016FY, 2017

    Revenue

    		9.9m

    Cost of goods sold

    		2.8m4.8m

    Gross profit

    		5.1m

    Gross profit Margin, %

    		51%
    Quarterly
    USDQ3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

    Revenue

    		773.0k1.5m2.0m2.8m1.3m2.7m3.0m

    Cost of goods sold

    		644.0k823.0k990.0k1.3m769.0k1.7m1.4m

    Gross profit

    		129.0k649.0k973.0k1.5m577.0k1.0m1.6m

    Gross profit Margin, %

    		17%44%50%53%43%37%53%
    show all
    Annual
    USDFY, 2016FY, 2017

    Cash

    		73.0m21.1m

    Accounts Receivable

    		2.9m4.2m

    Inventories

    		827.0k1.4m

    Current Assets

    		78.1m51.8m
    Quarterly
    USDQ3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

    Cash

    		2.3m41.7m5.8m12.1m33.5m24.2m21.6m

    Accounts Receivable

    		1.0m1.8m2.5m

    Inventories

    		438.0k928.0k747.0k911.0k1.9m1.8m2.0m

    Current Assets

    		18.0m69.7m63.9m57.8m39.1m31.0m35.3m
    show all
    Annual
    USDFY, 2016FY, 2017

    Net Income

    		(20.5m)(34.8m)

    Depreciation and Amortization

    		192.0k330.0k

    Inventories

    		(464.0k)(591.0k)

    Accounts Payable

    		46.0k624.0k
    Quarterly
    USDQ3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

    Net Income

    		(13.0m)(7.7m)(15.5m)(24.6m)(12.1m)(21.9m)(28.6m)

    Depreciation and Amortization

    		142.0k66.0k136.0k221.0k129.0k276.0k428.0k

    Inventories

    		(75.0k)(101.0k)80.0k(84.0k)(449.0k)(424.0k)(537.0k)

    Accounts Payable

    		519.0k217.0k58.0k534.0k1.1m275.0k135.0k
    show all
    USDY, 2018

    Financial Leverage

    		1.8 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    AristaMD
    Healthcare - Private
    UroMems
    Healthcare - Private
    VisCardia
    Healthcare - Private
    Respicardia
    Healthcare - Private
    Compare competitors

    Obalon Therapeutics News and Updates

    December 27, 2018

    Obalon Therapeutics, Inc. Announces Two Agreements To Provide Up To $30 Million of Capital

    SAN DIEGO, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has entered into …
    September 26, 2018

    Global Intragastric Balloons Market 2018-2022 - Key Vendors are Allurion Technologies, Apollo Endosurgery, Helioscopie, Obalon Therapeutics, ReShape Lifesciences & Spatz FGIA

    DUBLIN, Sept. 26, 2018 /PRNewswire/ -- The "Global Intragastric Balloons Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global Intragastric Balloons Market to grow at a CAGR of 25.18% during the period 2018-2022. The report has been prepared based on an...
    August 23, 2018

    Obalon Therapeutics to Raise $10 Million in Private Placement

    SAN DIEGO, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN) a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has entered into a…
    May 12, 2018

    Obalon Therapeutics' (OBLN) CEO Andrew Rasdal on Q1 2018 Results - Earnings Call Transcript

    Report incorrect company information

    Obalon Therapeutics Blogs

    June 08, 2018

    FDA Letter to Health Care Providers Related to Potential Risks, Including Death, with Liquid-Filled Intragastric Balloons for Weight Loss NOT Related to The Obalon Gas-Filled Balloon

    No Reports of Deaths Related to Use of Obalon Six-Month Balloon System SAN DIEGO – […]

    Obalon Therapeutics Company Life and Culture

    Report incorrect company information
    Download PDF

     Obalon Therapeutics Frequently Asked Questions

    • When was Obalon Therapeutics founded?

      Obalon Therapeutics was founded in 2008.

    • Who are Obalon Therapeutics key executives?

      Obalon Therapeutics's key executives are Mark Brister and Nooshin Hussainy.

    • How many employees does Obalon Therapeutics have?

      Obalon Therapeutics has 91 employees.

    • What is Obalon Therapeutics revenue?

      Latest Obalon Therapeutics annual revenue is $9.9 m.

    • What is Obalon Therapeutics revenue per employee?

      Latest Obalon Therapeutics revenue per employee is $108.9 k.

    • Who are Obalon Therapeutics competitors?

      Competitors of Obalon Therapeutics include AristaMD, UroMems and VisCardia.

    • Where is Obalon Therapeutics headquarters?

      Obalon Therapeutics headquarters is located at f 5421 Avenida Encinas, Carlsbad.

    • Where are Obalon Therapeutics offices?

      Obalon Therapeutics has an office in Carlsbad.

    • How many offices does Obalon Therapeutics have?

      Obalon Therapeutics has 1 office.